These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23873254)

  • 41. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema.
    Santos AR; Gomes SC; Figueira J; Nunes S; Lobo CL; Cunha-Vaz JG
    Ophthalmologica; 2014; 231(1):16-22. PubMed ID: 24280908
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.
    Ghanbari H; Kianersi F; Sonbolestan SA; Abtahi MA; Akbari M; Abtahi ZA; Abtahi SH
    Int Ophthalmol; 2017 Aug; 37(4):867-874. PubMed ID: 27624173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.
    ; Scott IU; Edwards AR; Beck RW; Bressler NM; Chan CK; Elman MJ; Friedman SM; Greven CM; Maturi RK; Pieramici DJ; Shami M; Singerman LJ; Stockdale CR
    Ophthalmology; 2007 Oct; 114(10):1860-7. PubMed ID: 17698196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema.
    Framme C; Schweizer P; Imesch M; Wolf S; Wolf-Schnurrbusch U
    Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5814-8. PubMed ID: 22836760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
    Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
    Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes.
    Yanyali A; Aytug B; Horozoglu F; Nohutcu AF
    Am J Ophthalmol; 2007 Jul; 144(1):124-6. PubMed ID: 17601433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
    Wiley HE; Thompson DJ; Bailey C; Chew EY; Cukras CA; Jaffe GJ; Lee RW; Loken EK; Meyerle CB; Wong W; Ferris FL
    Ophthalmology; 2016 Apr; 123(4):841-9. PubMed ID: 26875003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
    Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
    Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravitreal bevacizumab treatment for refractory diabetic macular edema.
    Yuksel E; Ozdek S; Yuksel N; Hasanreisoglu B
    Int Ophthalmol; 2013 Dec; 33(6):659-63. PubMed ID: 23508574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema.
    Forte R; Cennamo GL; Finelli M; Farese E; D'Amico G; Nicoletti G; de Crecchio G; Cennamo G
    Eye (Lond); 2010 Aug; 24(8):1325-30. PubMed ID: 20300127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema.
    Goyal S; Lavalley M; Subramanian ML
    Graefes Arch Clin Exp Ophthalmol; 2011 Jan; 249(1):15-27. PubMed ID: 20665044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors Influencing Intravitreal Bevacizumab and Triamcinolone Treatment in Patients with Diabetic Macular Edema.
    Kim TK; Shin HY; Kim SY; Lee YC; Lee MY
    Eur J Ophthalmol; 2017 Nov; 27(6):746-750. PubMed ID: 28430331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
    Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
    Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema.
    Liu MM; Wolfson Y; Bressler SB; Do DV; Ying HS; Bressler NM
    Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1370-7. PubMed ID: 24526445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CORRELATION OF OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI WITH VISUAL OUTCOMES IN DIFFERENT PATTERNS OF DIABETIC MACULAR EDEMA.
    Kang JW; Chung H; Chan Kim H
    Retina; 2016 Sep; 36(9):1630-9. PubMed ID: 26900741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
    JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma.
    Mashayekhi A; Rojanaporn D; Al-Dahmash S; Shields CL; Shields JA
    Eur J Ophthalmol; 2014; 24(2):228-34. PubMed ID: 23934823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group.
    Arevalo JF; Lasave AF; Wu L; Acon D; Farah ME; Gallego-Pinazo R; Alezzandrini AA; Fortuna V; Quiroz-Mercado H; Salcedo-Villanueva G; Maia M; Serrano M; Rojas S;
    Br J Ophthalmol; 2016 Dec; 100(12):1605-1610. PubMed ID: 26912377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Refractive changes after pharmacologic resolution of diabetic macular edema.
    Deák GG; Lammer J; Prager S; Mylonas G; Bolz M; Schmidt-Erfurth U;
    Ophthalmology; 2014 May; 121(5):1054-8. PubMed ID: 24439462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.